Year: 2021

PRESS RELEASE Immunocore to present at the Jefferies London Healthcare Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 11 November 2021) Immunocore (Nasdaq: IMCR), a late-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious and autoimmune disease, today announced that management will participate in a fireside chat at the Jefferies London Healthcare Conference, taking place November 16-19, 2021. The presentation will be available on-demand for attendees during the virtual conference beginning on November 18, 2021. The webcast can also be accessed in the ‘Investors’ section of Immunocore’s website at www.immunocore.com. ## About Immunocore Immunocore is...

WAYNE, Pa. and ROCKVILLE, Md., Nov. 11, 2021 (GLOBE NEWSWIRE) — Avalo Therapeutics, Inc. (Nasdaq: AVTX), a leading clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with significant unmet clinical need in immunology, immuno-oncology, and rare genetic diseases announced today that members of its senior management team will present at two upcoming conferences. Stifel 2021 Virtual Healthcare ConferenceDate: Wednesday, November 17, 2021Time: 4:00 PM ET Jefferies 2021 London Healthcare ConferenceDates: November 16-18, 2021A pre-recorded presentation will be available on-demand starting on Thursday, November 18, 2021 at 8:00 AM GMT. A live webcast of the presentation at the Stifel 2021 Virtual Healthcare Conference and pre-recorded presentation at the Jefferies 2021...

DURHAM, N.C., Nov. 11, 2021 (GLOBE NEWSWIRE) — Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced upcoming data presentations at the Society for Neuro-Oncology (SNO) Annual Meeting 2021, which will be held in Boston, MA from November 19-21, 2021. Details for the late-breaking plenary oral presentation are as follows: Title: Clinical efficacy of ONC201 in recurrent H3 K27M-mutant diffuse midline glioma patientsAbstract Number: LTBK-05Date and Time: November 20, 2021 from 9:37 a.m. – 9:50 a.m. ETPresenter: Isabel Arrillaga-Romany, M.D., Ph. D., Massachusetts General Hospital Details for additional oral and poster presentations are as follows: Title: Single agent activity of ONC201 in non-midline...

– The 24-Megawatt Facility is Capable of 620 Petahash/Second – This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated August 16, 2021 to its short form base shelf prospectus dated August 12, 2021. TORONTO, Ontario and BROSSARD, Québec, Nov. 11, 2021 (GLOBE NEWSWIRE) — Bitfarms Ltd. (NASDAQ: BITF // TSXV: BITF), a global Bitcoin self-mining company, acquired a 24 Megawatt (MW) hydro power farm in Washington state, USA. To date, 4,000 Bitmain S19j Pro miners, capable of 400 petahash/second (PH/s), have already been installed under a 12 MW hosting agreement which began in July 2021 and was terminated upon the closing of the acquisition. Bitfarms plans to house approximately 6,200 Bitmain S19j Pro miners, capable of 620 PH/s, in the facility. Bitfarms has...

Sol-Gel attains a profitable quarter, reporting total revenues of $8.8 million, net income of $1.3 million and EPS of $0.06 Recently obtained FDA approval of TWYNEO®triggers a $3.5 million milestone payment from Galderma, and, together with the $4.0 million down payment from Galderma, a total of $7.5 million was recognized in Q3 Sol-Gel to receive $21 million over 24 months in exchange for the transfer of its rights to two marketed generic drugs and eight unapproved generic programs based on a new agreement with Padagis; Sol-Gel to retain collaboration rights on two programs related to four high-value candidates Sol-Gel’s cash runway expected to extend through the end of 2023 Sol-Gel’s focus remains on supporting Galderma to launch TWYNEO, and EPSOLAY®, subject to the approval of the latter, along with advancing its innovative new drug...

Patricia Drake appointed new Chief Commercial Officer CHESTERBROOK, Pa., Nov. 11, 2021 (GLOBE NEWSWIRE) — Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced the addition of Patricia Drake to its senior leadership team as Chief Commercial Officer. ‘I am thrilled to have Pattie join our executive team and help us bring OLINVYK to the next level,” said Carrie Bourdow, President and CEO of Trevena. “Pattie brings more than 30 years of experience successfully launching multiple products in the hospital market and will be a welcomed addition to our experienced leadership team. She has already begun working on an accelerated plan to drive formulary wins, expand OLINVYK’s target opportunities,...

GONZALES, La., Nov. 11, 2021 (GLOBE NEWSWIRE) — Crown Crafts, Inc. (NASDAQ-CM: CRWS) (the “Company”) today announced that Olivia W. Elliott, President and Chief Operating Officer, and Craig J. Demarest, Vice President and Chief Financial Officer, will present at the Southwest IDEAS Investor Conference on Wednesday, November 17, 2021, at The Westin Dallas Downtown in Dallas, Texas. Management is scheduled to present at 8:45 a.m. Central Standard Time. The presentation will be webcast live and may be accessed at the conference host’s main website, www.IDEASconferences.com and in the investor relations section of the Company’s website, www.crowncrafts.com.   A replay of the webcast will be available for 90 days after the presentation, which may be accessed at https://wsw.com/webcast/threepa36/crws/2247054. About IDEAS Investor Conferences The...

MONTREAL, Nov. 11, 2021 (GLOBE NEWSWIRE) — Kintavar Exploration Inc. (the “Corporation” or “Kintavar”) (TSX-V: KTR) (FRANKFURT: 58V), is pleased to announce that it has closed a non-brokered private placement (the “Offering”) and issued 6,226,297 units of the Corporation (each a “Unit”) at a price of $0.17 per Unit and 9,702,447 common shares of the Corporation (each a “Share”), issued on a flow through basis, at a price of $0.23 per Share, for total cumulative gross proceeds of $3,290,033. Each Unit being comprised of one (1) Share and one half of one (1/2) Share purchase warrant, each whole warrant entitling the holder hereof to acquire one (1) Share at a price of $0.23 per Share until November 10, 2023. The Offering is subject to final acceptance of the TSX Venture Exchange. “After an exciting summer season full of discoveries...

MONACO, Nov. 11, 2021 (GLOBE NEWSWIRE) — Scorpio Tankers Inc. (NYSE: STNG) (“Scorpio Tankers” or the “Company”) today reported its results for the three and nine months ended September 30, 2021. The Company also announced that its Board of Directors has declared a quarterly cash dividend of $0.10 per share on the Company’s common stock. Results for the three months ended September 30, 2021 and 2020 For the three months ended September 30, 2021, the Company had a net loss of $73.3 million, or $1.34 basic and diluted loss per share.   For the three months ended September 30, 2021, the Company had an adjusted net loss (see Non-IFRS Measures section below) of $76.1 million, or $1.39 basic and diluted loss per share, which excludes from the net loss a $2.9 million, or $0.05 per basic and diluted share, gain...